Document Detail

Biodistribution and in vivo efficacy of genetically modified human mesenchymal stem cells systemically transplanted into a mouse bone fracture model.
MedLine Citation:
PMID:  23615814     Owner:  NLM     Status:  Publisher    
Human mesenchymal stem cells (hMSCs) have generated a great deal of interest in clinical application due to their ability to undergo multi-lineage differentiation. Recently, ex vivo genetic modification of hMSCs was attempted to increase their differentiation potential. The present study was conducted to evaluate the biodistribution and in vivo efficacy of genetically modified hMSCs. To accomplish this, Runx2, which is a key transcription factor associated with osteoblast differentiation, was transduced into hMSCs using lentiviral vectors expressing green fluorescent protein (GFP) or luciferase. Here, we developed an experimental fracture in mice femur to investigate the effects of Runx2-transduced hMSCs on bone healing and migration into injury site. We conducted bio-luminescence imaging (BLI) using luciferase-tagged vector and quantitative real-time PCR using GFP probe to investigate the biodistribution of Runx2-transduced hMSCs in the fracture model. The biodistribution of hMSC cells in the fractured femur was observed at 14 days post-transplantation upon both BLI imaging and real-time PCR. Moreover, the fractured mice transplanted with Runx2-transduced hMSCs showed superior bone healing when compared to mock-transduced hMSC and MRC5 fibroblasts which were used as control. These data suggested that transplanted genetically modified hMSCs systemically migrate to the fractured femur, where they contribute to bone formation in vivo.
Jin Wook Kang; Ki Dae Park; Youngju Choi; Dae Hyun Baek; Wan-Seob Cho; Mina Choi; Jae Hyun Park; Kyoung Suk Choi; Hyung Soo Kim; Tae Moo Yoo
Related Documents :
24281054 - Association of matrix gla protein gene functional polymorphisms with loss of bone miner...
24269824 - Increased col10a1 expression is not causative for the phenotype of phex-deficient hyp m...
23871514 - Monitoring tissue inflammation and responses to drug treatments in early stages of mice...
23059814 - Suppression of mammalian bone growth by membrane transport inhibitors.
19706004 - Iliotibial band syndrome: an examination of the evidence behind a number of treatment o...
20512784 - Two-stage revision of hip prosthesis infection using a hip spacer with stabilising prox...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-4-25
Journal Detail:
Title:  Archives of pharmacal research     Volume:  -     ISSN:  0253-6269     ISO Abbreviation:  Arch. Pharm. Res.     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-4-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8000036     Medline TA:  Arch Pharm Res     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Biotechnological Development Assistance Team, National Institute of Food and Drug Safety Evaluation, Korea Food & Drug Administration, Osong Health Technology Administration Complex, 187 Osongsaengmyeong2(i)-ro, Osong-eup, Chengwon-gun, Chungcheongbuk-do, 363-700, Republic of Korea,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Structural and functional neuroimaging studies in major depressive disorder with psychotic features:...
Next Document:  Selective aerobic oxidation of amines to imines by TiO2 photocatalysis in water.